The Eonis screening assay from PerkinElmer, Waltham, Mass, has received CE-IVD approval. The assay for newborns simultaneously tests for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency) and XLA (X-linked agammaglobulinemia).
This IVD RT-PCR assay integrates into PerkinElmer’s entire newborn screening workflow to provide labs with a complete, single source solution encompassing everything from sample to solution.
SMA is one of the most common lethal recessive genetic conditions and is associated with significant motor disability, respiratory issues, and nutritional compromise. SCID, known more commonly as “Bubble Boy” disease, is a rare condition, caused by a severe defect in the immune system that makes it difficult or impossible to fight off infections. XLA, most common in males, is a rare genetic disorder that affects the body’s ability to fight infection. All three diseases can be fatal if not detected at birth before symptoms appear, making early screening imperative to identify affected children so that the proper care can be conducted.
The design of the Eonis assay enables automation with Janus Liquid Handlers to further streamline the workflow of high-throughput laboratories without compromising the sample traceability from punch to result. The traceable dried blood spot workflow consists of five main elements to detect SMA, SCID, and XLA: sample collection, punching, DNA extraction, amplification, and data analysis utilizing dedicated analysis software.
“The global availability of this CE-marked assay for SMA, SCID, and XLA will have a profound impact. It will help save lives and dramatically improve clinical outcomes for children by ensuring treatment can be given earlier to those who need it,” says Petra Furu, GM, Reproductive Health, PerkinElmer. “The integration of this assay with our complete workflow solution is a prime example of how PerkinElmer is providing laboratories with the innovative tools needed to run a reliable, and yet, cost-effective screening program.”
For more information, visit PerkinElmer.